Ramcharran, Darmendra
Strober, Bruce
Gordon, Kenneth
DeKlotz, Cynthia
Fakharzadeh, Steven
Yang, Ya-Wen
Swerdel, Joel
Hardin, Jill
Dronavalli, Sridhar
Paller, Amy S.
Funding for this research was provided by:
Janssen Research and Development
Article History
Received: 22 June 2023
Accepted: 29 August 2023
First Online: 22 September 2023
Declarations
:
: At the time the research was conducted, Darmendra Ramcharran was an employee of Janssen Research & Development; he is currently an employee of GSK. Bruce Strober served as a consultant (honoraria) and/or speaker and/or investigator for AbbVie, Almirall, Amgen, Arcutis, Arena, Aristea, Asana, Boehringer Ingelheim, Bristol Myers Squibb, Cara, Connect Biopharma, CorEvitas Psoriasis Registry, Dermavant, Dermira, Eli Lilly, EPI Health, Evelo Biosciences, Immunic Therapeutics, Incyte, Janssen, LEO Pharma, Maruho, Meiji Seika Pharma, Mindera Health, Novartis, Ono, Pfizer, Regeneron, Sanofi-Genzyme, Sun Pharma, UCB Pharma, Union Therapeutics, Ventyxbio, and vTvt Therapeutics; served as co-Scientific Director (consulting fee) of CorEvitas (formerly Corrona) Psoriasis Registry and Editor-in-Chief (honorarium) of <i>Journal of Psoriasis and Psoriatic Arthritis</i>. Kenneth Gordon received research/grant support from AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen, Novartis, and UCB Pharma, and honoraria for consultation from AbbVie, Amgen, Boehringer Ingelheim, Celgene, Dermira, Eli Lilly, Janssen, Novartis, and UCB Pharma. Amy Paller has been an investigator for AbbVie, Dermavant, Eli Lilly, Incyte, Janssen, Krystal, and UCB; a consultant with honorarium for Aegerion Pharma, Azitra, BioCryst, Boehringer Ingelheim, Bristol Myers Squibb, Castle Creek, Eli Lilly, Janssen, Krystal, LEO Pharma, Novartis, Regeneron, Sanofi/Genzyme, Seanergy, TWI Biotechnology, and UCB; and is on data safety monitoring boards for AbbVie, Abeona, Catawba, Galderma, and InMed. Cynthia DeKlotz, Joel Swerdel, and Jill Hardin are employees of Janssen Research & Development and Steven Fakharzadeh and Ya-Wen Yang are employees of Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson; employees may own stock in Johnson & Johnson, of which Janssen is a subsidiary. Sridhar Dronavalli has no conflicts to disclose.
: The Optum and IBM MarketScan databases used in this study were reviewed by the New England Institutional Review Board (IRB) and were determined to be exempt from broad IRB approval, as this research project did not involve human subject research. Based on Ethical Guidelines for Epidemiological Research issued by the Japanese Ministry of Health, Labor and Welfare, ethics approval and informed consent for the JMDC database were not applicable for this study.